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Age-related loss of muscle mass has received 
increased attention over the past two decades 
from both clinician and basic science researchers.1 
Evans and Campbell labeled the age-related loss of 
muscle mass as sarcopaenia (Greek sarx=flesh and 
paenia=loss).2 The estimated relative annual rate of 
loss of muscle mass is 1% in men and 0.84% in women.1 
The average age of onset of decline in muscle mass is 
approximately 40 years and progress in a linear fashion 
to reach approximately 50% by the 8th decade.3,4 
Sarcopaenia is characterised by a decrease in muscle 
mass and cross-sectional area, the infiltration of muscle 
by fat and connective tissue, a decrease of type 2 
muscle fiber size and number, and also a decrease 
of the number of type 1 fibers.5 In addition to muscle 
atrophy, a decline in muscle quality and function also 
plays a part in muscle dysfunction of aging.6 Changes 
in muscle quality in aged subjects include a decreased 
concentration of myosin, the most important motor 
protein; fewer cross-bridges per muscle fiber area; 
post-translational chemical modifications of the myosin 
molecule such as protein methylation, glycosylation, 
and/or oxidation; and finally, a decrease in muscle 
elasticity.6 The decline in physical activity frequently 
accompanying aging may also exert synergistic 
effects on these changes. Furthermore, the regulation 
of skeletal muscle mass and regeneration is intricately 
linked to skeletal muscle metabolism and the 
recruitment of skeletal muscle stem cells - also referred 
to as satellite cells.7 
The mechanisms underlying sarcopaenia of aging 
are numerous and include endocrine conditions, 
age-related changes in sexual hormones, apoptosis, 
mitochondrial dysfunction, neuro-degenerative 
conditions, inflammation, disuse, malnutrition, and 
cachexia associated with serious underlying disease 
states.5 The end result, however, is an imbalance 
between muscle protein synthesis and breakdown 
with a disproportionately higher rate of breakdown 
over a prolonged period.1 The mammalian target of 
rapamycin complex 1 (mTORC1) signaling pathway 
in muscle plays a key role in regulating exercise-
induced protein synthesis.8 Fry et al demonstrated that 
aging impairs contraction-induced human skeletal 
muscle mTORC1 signaling and protein synthesis.9 
This observation may partially explain the blunted 
hypertrophic response observed after resistance 
exercise training in older adults and highlights the 
mTORC1 pathway as a potential therapeutic target for 
pharmacological intervention in sarcopaenia.9
The European Working Group on Sarcopaenia in 
Older People (EWGSOP) recognises sarcopaenia as a 
geriatric syndrome characterised by progressive and 
generalised loss of muscle mass and strength with a 
risk of adverse outcomes such as physical disability, 
poor quality of life and death.10 EWGSOP suggests 
the following diagnostic criteria for sarcopaenia:10 
the presence of low muscle mass and low muscle 
function defined by either loss of muscle strength 
or performance. Dual energy X-ray absorptiometry 
(DXA) has become the gold standard in measuring 
muscle mass in clinical practice as part of body 
composition assessment.10,11 Bio-impedance analysis 
(BIA) may be an affordable and portable alternative 
to DXA.10 Muscle strength can be measured in various 
ways of which measuring handgrip strength with a 
handheld dynamometer is the most popular.11 Physical 
performance can be measured in a variety of ways of 
which either the Short Physical Performance Battery 
(SPPB), with gait speed over 4 meters; or the “timed-
get-up-and-go test” (TGUGT) is most popular in the 
clinical setting.10,11 Cut-points for these frequently-used 
criteria are readily available.11
The prevalence of sarcopaenia in the elderly 
differs widely according to methodology used and 
population studied. Morley estimated the prevalence 
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of sarcopaenia to be 5-13% in 60-70 year-old persons 
and 11-50% in those 80 years and above.12 The clinical 
consequences of sarcopaenia are future disability,13 
mobility limitation,14 and impaired quality of life.11 
Obese older people with reduced handgrip strength 
are particularly at risk of walking limitation.11 Lower 
grip strength is also positively associated with future 
fracture risk, cognitive decline, coronary heart disease, 
hospitalisation, risk of falling, and death.11
Cruz-Jentoft et al recently reviewed published 
interventions to prevent or improve sarcopaenia.15 
Exercise intervention may have a role in increasing 
muscle strength and improving physical performance 
although the impact of exercise training is inconsistent 
in improving muscle mass in frail elderly individuals. 
The effect of nutrition intervention in terms of protein 
and Vitamin D supplementation is uncertain due to 
methodological problems in the design of most studies. 
Some studies report encouraging findings in terms of 
essential amino acid supplementation in the form of 
leucine and HMB (β-hydroxy β-methylbutyric acid), the 
active metabolite of leucine, alone or in addition to 
exercise training. 
The International Sarcopaenia Initiative (ISI) concluded 
in a recent review that sarcopaenia is present in at least 
1 in 20 community dwelling individuals and in as many 
as 1 in 3 frail older people living in nursing homes.15 
The ISI urge clinicians to screen for the presence of 
sarcopaenia both in community as well as geriatric 
settings and to consider supervised resistance exercise 
training for periods of at least 3 months. The ISI also 
supports the recommendation of the PROT-AGE study 
group to increase protein intake of elderly people 
(65-years and older) to 1.0-1.2 g/kg per day to help 
them regain and maintain lean body mass.16
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